mHTT

D01 Two independent validations of a mutant huntingtin protein (MHTT) assay to support the clinical development of mHTT-targeting therapies in HD
David Hawellek, Stephanie Vauleon, Katharina Schutz, Benoit Massonnet, Nanda Gruben, Marianne Manchester, Lauren Boak, Scott Schobel

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A13; DOI: 10.1136/jnnp-2021-EHDN.32
I04 Aav5-mihtt gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington disease minipigs up to 4 years
Leontien van der Bent, Cynthia Brouwers, Robin Pocornie, Anouk Stam, Steffi Jonk, Jiří Klíma, Stefan Juhás, Jan Motlík, Melvin Evers, Zdenka Ellederovaé, Astrid Vallès

Journal of Neurology, Neurosurgery & Psychiatry Sep 2022, 93 (Suppl 1) A86; DOI: 10.1136/jnnp-2022-ehdn.230
D07 Development of luminex xmap bead-based immunoassay for quantification of MHTT
Katerina Vodickova Kepkova, Petr Vodicka

Journal of Neurology, Neurosurgery & Psychiatry Sep 2018, 89 (Suppl 1) A33; DOI: 10.1136/jnnp-2018-EHDN.89
B33 Decreased heart mass and dysregulated cardiac mTORC1 activity are associated with huntington’s disease
Daniel Child, John Lee, Beverly L Davidson

Journal of Neurology, Neurosurgery & Psychiatry Sep 2016, 87 (Suppl 1) A20-A21; DOI: 10.1136/jnnp-2016-314597.64
L10 Two novel mtor and PI3K/mTOR inhibitors induce autophagy and reduce the amount of aggregated mutant huntingtin in cell models of HD
Elisabeth Singer, Carolin Walter, Petra Hillmann, Doriano Fabbro, Olaf Riess, Huu P Nguyen

Journal of Neurology, Neurosurgery & Psychiatry Sep 2016, 87 (Suppl 1) A93; DOI: 10.1136/jnnp-2016-314597.265

Log in using your username and password

Main menu

Log in using your username and password

You are here

mHTT